Login to Your Account



Financings NEWS

Despite freer-flowing capital for biotech, Foresite Capital closed its third and largest fund at $450 million, and "our strategy hasn't changed," Christine Aylward, managing director, told BioWorld Today.

FIRST DAY SHARE PRICE 'ACTIVATED'
The robust health care sector along with an investor passion for immuno-oncology helped Nantkwest Inc. to its $207 million IPO, selling 8.3 million shares at $25 each, above the targeted $20 to $23 price range and 1.3 million more shares than planned.

Biosimilars developer Oncobiologics Inc. has landed a $31 million financing to support continued expansion and development of its platform and pipeline, which includes clinical-stage biosimilars of HumiraAvastin and nine other preclinical candidates poised to take on off-patent biologics.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: